Annexin A2 autoantibodies in thrombosis and autoimmune diseases.

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial, venous or small-vessel thrombotic events, and recurrent miscarriages or fetal loss. APS diagnosis is based on the repeated detection of anti-phospholipid (PL) antibodies (Ab), typically associated with anti-β2 glycoprotein I (β2GPI)-Ab. Recent studies suggest that anti-β2GPI Ab activity involves a protein complex including β2GPI and annexin A2 (ANXA2). Anti-ANXA2 Ab recognizes this complex, and these Ab can effectively promote thrombosis by inhibiting plasmin generation, and by activating endothelial cells. Therefore, anti-ANXA2 Ab represent a new biomarker, which can be detected in up to 25% of APS patients. Moreover, anti-ANXA2 Ab have been detected, in thrombotic associated diseases including pre-eclampsia, in other autoimmune diseases, and in cancer.

• Authors: Felipe Cañas, Laurent Simonin, Francis Couturaud, Yves Renaudineau
• Journal: Thrombosis research (Thromb Res) Vol. 135 Issue 2 Pg. 226-30 (Feb 2015) ISSN: 1879-2472 [Electronic] United States
• PMID: 25533130 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Elsevier Ltd. All rights reserved.

Chemical References

• Annexin A2
• Autoantibodies

Topics

• Annexin A2 (metabolism)
• Antiphospholipid Syndrome (immunology)
• Autoantibodies (immunology)
• Autoimmune Diseases (immunology)
• Humans
• Thrombosis (immunology)